Peptides

Peptides for Weight Loss: GLP-1, Tesamorelin, and What Actually Works

Medically reviewed by Medical Advisory Board Last reviewed 2026-08-19

A science-based ranking of weight-loss peptides — from FDA-approved GLP-1 agonists to research compounds

Peptides for weight loss range from FDA-approved GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) producing 15–24% average body weight loss, to growth hormone secretagogues that reduce visceral fat without appetite suppression. This guide ranks peptide options by evidence strength, access, and expected results.

"Peptides for weight loss" covers a wide spectrum — from blockbuster medications generating $10B+ in annual revenue to research compounds sold to hobbyists. The mechanism, evidence base, expected results, and legal status vary enormously across these compounds. This guide sorts through the noise.

The 40,500 monthly searches for "peptides for weight loss" reflect genuine demand from people who want to understand their options beyond Ozempic. The honest answer: GLP-1 peptides are in a category of their own for pure weight loss efficacy. Other peptides (growth hormone secretagogues like the CJC-1295 + ipamorelin stack, tesamorelin) address body composition more specifically — reducing visceral fat and improving lean mass — rather than driving the scale down directly.

Want expert help with your metabolic health?

We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.

Book An Appointment With A Specialist →

Weight loss resistance is often rooted in insulin resistance — a metabolic condition where cells become less responsive to insulin, promoting fat storage. Understanding whether your weight challenges are metabolic vs. behavioral changes which peptide approach is most appropriate. Our insulin resistance calculator can help you assess your metabolic baseline.

Peptides for Weight Loss: Ranked by Evidence

Peptide	Mechanism	Avg. Weight Loss	Evidence Level	Access
Semaglutide (Ozempic/Wegovy)	GLP-1 receptor agonist — appetite suppression, slowed gastric emptying	14.9% (STEP 1 trial)	Phase III RCT ✓✓✓	Prescription only
Tirzepatide (Mounjaro/Zepbound)	Dual GIP/GLP-1 agonist — superior appetite + incretin effects	22.5% (SURMOUNT-1 trial)	Phase III RCT ✓✓✓	Prescription only
Retatrutide	Triple GIP/GLP-1/glucagon agonist — in Phase III	24.2% at 48 weeks (Phase II)	Phase II/III trial ✓✓	Not yet approved
Tesamorelin	GHRH analog — reduces visceral fat specifically; minimal scale weight effect	15–20% visceral fat reduction	FDA-approved (HIV lipodystrophy); Phase II data in obesity ✓✓	Prescription; compounded
Ipamorelin + CJC-1295	GH secretagogues — improve body composition, not direct fat loss	Modest (body recomp focus)	Small studies ✓	Compounded / research
AOD-9604	GH fragment — lipolytic effect; failed Phase III	Modest at best	Failed Phase III ✗	Research chemical only

GLP-1 Peptides: The Clear Leaders

Semaglutide (Ozempic for diabetes, Wegovy for obesity) and tirzepatide (Mounjaro for diabetes, Zepbound for obesity) are GLP-1 receptor agonists — peptide-based drugs that produce weight loss primarily through appetite suppression and slowed gastric emptying. The STEP 1 trial showed average weight loss of 14.9% of body weight over 68 weeks on semaglutide 2.4 mg. The SURMOUNT-1 trial showed 22.5% average weight loss on tirzepatide 15 mg.

Retatrutide — a triple agonist targeting GIP, GLP-1, and glucagon receptors — showed 24.2% average weight loss at 48 weeks in Phase II data. Phase III trials are ongoing. If results hold, it may become the most effective weight-loss drug ever approved.

These are the only peptides where the evidence clearly supports expecting significant (>10%) body weight reduction in the majority of patients.

Growth Hormone Peptides: Body Composition vs. Weight Loss

Growth hormone secretagogues (ipamorelin, sermorelin, CJC-1295, tesamorelin) are often marketed for weight loss, but their primary effect is on body composition — not scale weight. They work by stimulating your pituitary to release more growth hormone, which:

Reduces visceral fat: GH selectively mobilizes visceral adipose tissue. Tesamorelin specifically reduced visceral fat by 15–20% in FDA trials.
Increases lean muscle mass: GH is anabolic. Users often simultaneously lose fat while gaining muscle — meaning the scale may not move much even as body composition improves significantly.
Improves sleep quality: GH is predominantly released during slow-wave sleep. Better GH pulses improve sleep architecture, which in turn supports fat metabolism.

If your goal is specifically to see the scale move, GH peptides will likely disappoint. If your goal is to reduce abdominal fat and improve body composition — while maintaining or building muscle — they can be genuinely effective. The combination of ipamorelin + CJC-1295 is the most commonly used GH stack for body recomposition.

Tesamorelin for Visceral Fat

Tesamorelin is the standout peptide for targeted visceral fat reduction. FDA-approved for HIV-associated lipodystrophy (abnormal abdominal fat), its mechanism is relevant to anyone with excess visceral fat — a common feature of metabolic syndrome, insulin resistance, and post-menopausal fat redistribution.

Clinical data shows 15–20% reduction in visceral adipose tissue over 26 weeks. Unlike GLP-1 agonists, tesamorelin doesn't strongly suppress appetite — it works through a different mechanism entirely (GH stimulation → IGF-1 → lipolysis). This makes it useful for people who want to target abdominal fat without the GI side effects of GLP-1 drugs.

Access outside of HIV lipodystrophy requires working with a provider who prescribes it off-label — it remains available through compounding pharmacies for body composition purposes.

Peptides That Don't Work for Weight Loss

Several peptides are frequently marketed for weight loss without supporting evidence:

AOD-9604: A GH fragment marketed heavily in the supplement space. Failed Phase III trials for obesity. Does not produce meaningful weight loss in humans at tolerable doses.
HCG (human chorionic gonadotropin): The FDA has explicitly stated the HCG diet is "dangerous and illegal." The weight loss seen on HCG protocols is from the accompanying 500-calorie diet, not the hormone. HCG does not cause fat mobilization as claimed.
MK-677 (ibutamoren): A non-peptide GH secretagogue. While it raises IGF-1 and GH, it does NOT cause weight loss — it significantly increases appetite. Many users gain weight due to water retention and increased food intake.

How to Take Weight-Loss Peptides: Dosing, Timing, and Results Timeline

Weight-loss peptides start at a low dose and increase gradually. The exact schedule depends on which compound you're using.

GLP-1 injectables like semaglutide and tirzepatide use a weekly dose-escalation schedule. A prescriber raises the dose every few weeks. This slow ramp-up reduces nausea and other GI side effects during the first months.

Tesamorelin and growth hormone secretagogues follow a separate schedule set by the prescribing clinician. They work through a different pathway than GLP-1 drugs, so the titration pattern differs too.

This guide does not list exact milligram doses, since the right amount depends on the specific peptide, your labs, and your prescriber's judgment. For the practical mechanics of mixing and injecting a peptide correctly, see our peptide reconstitution guide.

Results build over weeks, not days. The ranking table above reflects trial data spanning 48 to 68 weeks, and most participants see the bulk of their weight change accumulate over several months of consistent use. Growth hormone peptides move on an even slower timeline, since body composition changes lag behind hormone changes.

If weight loss stalls despite consistent use, that's common and usually has an identifiable cause. See our GLP-1 plateau guide for the specific mechanisms behind a stall and what to do next.

Cost, Access, and Where to Buy

Weight-loss peptide costs vary widely by class and access method. Branded GLP-1 injectables like semaglutide and tirzepatide list at roughly $1,000 per month without insurance, the same figure cited in our GLP-1 peptide guide. Compounded growth hormone secretagogue blends, like CJC-1295 paired with ipamorelin, typically run $150 to $350 per month. Tesamorelin costs $3,000 to $5,000 per month without insurance at its FDA-approved brand-name price, and insurance usually covers it only for HIV-associated lipodystrophy, not general weight loss, as detailed in our peptide therapy cost breakdown.

Real weight-loss peptides are not sold at general retailers, pharmacies, or supplement stores. Amazon, Walmart, CVS, Costco, GNC, Target, and Vitamin Shoppe do not carry legitimate prescription GLP-1 drugs or genuine compounded peptides. Any product sold under these names at a general retailer is not the real medication.

Prescription requirements apply outside the US too. The UK, Canada, Australia, and the EU generally require a prescription for GLP-1 and similar weight-loss medications, the same as the US. Rules and availability shift often, so check with a local prescriber for current status in your country.

Peptides for Weight Loss in Women

Weight-loss peptide considerations shift for women at several life stages. Menopause redistributes body fat toward the abdomen, increasing visceral fat even without a change in total weight. This shift is part of why tesamorelin and GLP-1 peptides come up more often in conversations about post-menopausal weight management, since both target fat that concentrates in that pattern.

PCOS (polycystic ovary syndrome) frequently involves insulin resistance, which makes weight loss harder through diet and exercise alone. Some clinicians consider GLP-1 medications for PCOS patients with insulin resistance, based on the same insulin and appetite pathways these drugs act on in diabetes and obesity. This is a case-by-case clinical decision, not a blanket recommendation, and requires a prescriber familiar with PCOS.

Pregnancy and breastfeeding are separate considerations. Breastfeeding is generally a reason to avoid these medications; see the FAQ below for the full explanation.

Peptides Often Confused With Weight-Loss Peptides

Several peptides get confused with weight-loss peptides because of similar names. They serve different purposes.

MOTS-c is a separate, mitochondria-derived peptide studied for metabolic and exercise effects. It is not an approved weight-loss therapy. See our MOTS-c guide for what the research actually shows.
GLP-2 shares part of a name with GLP-1 but is a distinct intestinal peptide used to treat short-bowel syndrome. It does not suppress appetite or drive weight loss the way GLP-1 drugs do.
GHK-Cu is a copper peptide studied for skin and hair, not metabolism. See our peptides for skin guide for the evidence.
Collagen peptides are a food-derived supplement ingredient, not a metabolic drug. They support skin and joint structure, covered in our collagen peptides guide.
Peptide YY is a natural satiety-signaling peptide your gut already produces after eating. Its mechanism is related to GLP-1's appetite effects, but it is not itself a marketed weight-loss therapy.

What Reviews and Before/After Photos Don't Tell You

Online reviews and before/after photos show individual results, not the range of outcomes seen in clinical trials. A single dramatic photo says nothing about how typical that result is, what dose was used, or how long it took.

Clinical trial data, like the results cited in the ranking table above, comes from hundreds or thousands of participants tracked under controlled conditions. Anecdotal posts online come from a self-selected group who chose to share their results, which skews toward more dramatic outcomes.

Anyone evaluating a peptide source should look at the same markers our peptides guide recommends. Check for a certificate of analysis (COA) from an independent third-party lab for that specific batch. Also check whether the product is prescription-based or sold as an unregulated research chemical.

A prescription pathway through a licensed pharmacy remains the lowest-risk route for anyone using these peptides therapeutically.

What Form Do Weight-Loss Peptides Come In?

Weight-loss peptides come in three distinct forms, and only two of them are backed by clinical evidence. Injectable delivery is the standard for GLP-1 drugs, tesamorelin, and growth hormone secretagogues. These peptides break down in the digestive tract before they can act, so injection remains the primary route.

Oral tablets are the second option. Oral GLP-1 pills use a specific absorption-enhancer technology to survive stomach acid. See our oral GLP-1 pills comparison for how these compare to the injectable versions.

The third category is worth flagging clearly: gummies, drink mixes, and "peptide" powders sold in the general supplement aisle. These are marketing products, not the same product class as prescription or research peptides. No published clinical evidence supports weight loss from a peptide gummy or powder.

What to Look For in a Body-Composition Scale

A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.

GE Smart Scale for Body Weight: 8-Electrode Digital Bathroom Scale for Weight Fat BMI Muscle Mass Full Body Composition Analyzer 50 Measurements Bluetooth Highly Accurate Weighing Machine 400lb Black

View on Amazon →

Etekcity Smart Scale for Body Weight, FSA&HSA Eligible, Bathroom Digital Weighing Scale with BMI, Body Fat, Muscle Mass, Accurate Bluetooth Home User Health Equipment Sync Apps, LED, Tempered glass

Etekcity

View on Amazon →

Frequently Asked Questions

What peptide is best for weight loss?

For pure weight loss, semaglutide (Wegovy) and tirzepatide (Zepbound) are far ahead of all alternatives. They're FDA-approved prescription medications that produce average weight loss of 15–22% of body weight over 12–16 months. For targeted visceral fat reduction without scale weight loss, tesamorelin is the evidence-backed option. Growth hormone peptides (ipamorelin, CJC-1295) improve body composition but rarely move the scale significantly.

Do peptides really work for weight loss?

GLP-1 peptides (semaglutide, tirzepatide) absolutely work — they represent the most effective weight-loss pharmacotherapy ever developed, with clinical trial results that were previously considered impossible without surgery. Other peptides marketed for weight loss have much weaker evidence. The peptide category is broad, and effectiveness varies enormously by compound.

Can I use peptides for weight loss without a prescription?

The most effective weight-loss peptides (semaglutide, tirzepatide) require a prescription. Research peptides like ipamorelin and CJC-1295 can be obtained without a prescription from research chemical vendors, but are not approved for human use and have much weaker weight-loss evidence. Tesamorelin requires a prescription and is available through compounding pharmacies.

How much weight can you lose on peptides?

On GLP-1 peptides: average 15% (semaglutide) to 22% (tirzepatide) of body weight over 12-16 months, with some individuals losing 25-35%+. On growth hormone peptides: scale weight change is typically modest; the main benefit is body recomposition (losing fat while gaining muscle). On research peptides like BPC-157 or epithalon: no meaningful weight loss effect.

Are weight-loss peptides safe? What are the side effects and risks?

The safety picture is very different for FDA-approved GLP-1 drugs versus research peptides. Semaglutide and tirzepatide have a well-characterized side-effect profile from large trials: the most common issues are gastrointestinal (nausea, vomiting, diarrhea, constipation), usually worst during dose escalation and improving over time. Less common but more serious: acute pancreatitis and acute gallbladder disease (gallstones), both of which warrant stopping the drug and seeking care if suspected. Both drugs also carry an FDA boxed warning for thyroid C-cell tumors, based on findings in rodent studies (human risk is not established), and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Research peptides sold outside a clinical trial or pharmacy setting — ipamorelin, CJC-1295, and AOD-9604, along with retatrutide obtained from research-chemical vendors rather than through its ongoing trials — carry a different kind of risk: no FDA review for human use, no standardized manufacturing oversight, purity testing, or established dosing. The safety concern here is the absence of a known profile, not a specific documented one. For skin laxity or texture changes during rapid weight loss, see our Ozempic loose skin guide.

Do GLP-1 weight-loss peptides cause muscle loss?

Yes, to a meaningful degree — it's one of the most consistent findings across GLP-1 trials with body-composition data. A DEXA substudy of the STEP 1 trial found semaglutide users lost about 10% of their baseline lean body mass (Wilding et al., 2021), with lean mass making up roughly 40% of total weight lost — notably higher than the roughly 20-30% lean-mass share typically seen with diet-and-exercise weight loss alone. A similar substudy of SURMOUNT-1 found tirzepatide users lost about 11% of baseline lean mass, but because tirzepatide also produced larger fat losses, lean mass accounted for a smaller share of the total: roughly 25% (Look et al., 2025) — a proportion the study authors describe as comparable to what's typically seen with diet, exercise, and even bariatric surgery, rather than an added drug-specific risk. This is why obesity-medicine guidance increasingly recommends resistance training and adequate protein intake (roughly 1.0-1.2 g/kg body weight per day) throughout GLP-1 therapy — and it's part of why growth hormone secretagogues are sometimes used alongside GLP-1s rather than as a substitute, since they work through a mechanism that favors lean mass preservation rather than loss.

Are weight-loss peptides the same as Ozempic?

Not exactly — Ozempic (semaglutide) is one specific GLP-1 peptide, not the whole category. "Weight-loss peptides" is a broader label that includes GLP-1 drugs like semaglutide and tirzepatide (the strongest evidence for pure weight loss), plus a separate class of growth hormone secretagogues (ipamorelin, CJC-1295, tesamorelin) that work through a different mechanism and target body composition rather than the scale directly. So every GLP-1 weight-loss peptide works similarly to Ozempic, but not every weight-loss peptide is a GLP-1 drug — see the ranked comparison table above for how the mechanisms and evidence differ.

Who should not use weight-loss peptides?

Pregnant or breastfeeding women should not use weight-loss peptides. This matches the site's broader guidance on peptides during pregnancy and lactation. Safety data is lacking for most compounds in that population. See our peptides guide for that full explanation. GLP-1 drugs like semaglutide and tirzepatide are FDA-approved for type 2 diabetes and chronic weight management, not for type 1 diabetes. Using one off-label for type 1 diabetes needs direct evaluation by a prescriber, since insulin needs and hypoglycemia risk work differently in that condition. Anyone with a personal or family history of hormone-sensitive conditions should also talk to a physician before starting.

Can weight-loss peptides be combined with joint or recovery peptides?

Yes, and it's common for people managing joint pain or recovery to combine categories alongside a weight-loss protocol. Healing-focused peptides work through a different mechanism than GLP-1 or growth hormone peptides. There's no direct conflict between the two. See our peptides for healing guide and BPC-157 vs TB-500 comparison for the healing-specific options. Talk to your prescriber before combining any protocols.

Topic updates

Get the weekly peptide roundup

Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

Check Where You Stand

Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results